Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-272 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive a single dose of VX-272. |
| Placebo: Part A | PLACEBO_COMPARATOR | Participants will be randomized to receive a single dose of placebo matched to VX-272. |
| Part B: Multiple Ascending Dose | EXPERIMENTAL | Participants will be randomized to receive multiple doses of VX-272. |
| Placebo: Part B | PLACEBO_COMPARATOR | Participants will be randomized to receive multiple doses of placebo matched to VX-272. |
| Name | Type | Description |
|---|---|---|
| VX-272 | DRUG | Suspension for Oral Administration. |
| Placebo | DRUG | Suspension for Oral Administration. |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * A total body weight of more than (\>) 50 kg * Male and Female participants of non-childbearing potential Key Exclusion Criteria: * History of febrile illness or other acute illness that has not f...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
VX-272 is an investigational small molecule being developed for the treatment of Cystic Fibrosis. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug targets the CFTR protein, which is central to the disease.
VX-272 targets the CFTR protein, a channel involved in chloride transport across cell membranes. By modulating CFTR, the drug aims to address the underlying defect in Cystic Fibrosis. This target is a protein, and the drug is a small molecule designed to interact with it.
VX-272 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company. Vertex is listed on the stock exchange under the ticker VRTX. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of VX-272.
VX-272 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The ongoing Phase 1 trial is designed to assess safety and pharmacokinetics in healthy participants.
VX-272 is being studied in a Phase 1 trial with the identifier NCT07437105. This is a dose escalation study evaluating the safety and pharmacokinetics of VX-272 in healthy participants. The trial is recruiting and has an enrollment of 128 participants in the United States.
VX-272 is a distinct investigational compound developed by Vertex Pharmaceuticals. It is not known to be the same as any other marketed drug. Its unique mechanism targets the CFTR protein for the treatment of Cystic Fibrosis.